Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Withdrawn 1Terminated 1Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 14Breast 5Other hematologic neoplasm 3Sarcoma 2Gynecologic 2Plasma cell 1Myeloid 1Head & Neck 1Genitourinary 1Gastrointestinal 1Dermatologic 1Classical hematology 1CNS 1

Conditions

Sarcoma, Ewing 1Rhabdomyosarcoma 1Recurrence 1Osteosarcoma 1Neuroblastoma 1Lymphoma 1

Interventions

Temozolomide 80Radiotherapy 41Bevacizumab 35Radiosurgery 23Magnetic Resonance Spectroscopy 20Cyclophosphamide 17Radiation 14Irinotecan 13Carboplatin 12Topotecan 11Nivolumab 11Lomustine 11Filgrastim 10Everolimus 10Etoposide 10Erlotinib Hydrochloride 10pembrolizumab 9Radiotherapy, Intensity-Modulated 9Ipilimumab 9Granulocyte Colony-Stimulating Factor 8Carmustine 8antineoplaston AS 2-1 7antineoplaston A10 7Surgical Procedures, Operative 7Mental Status and Dementia Tests 7Isotretinoin 7Granulocyte-Macrophage Colony-Stimulating Factor 7sargramostim 6Vincristine 6TPI-287 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × copanlisib × CNS × Clear all
NCT03458728 2023-12-04

Safety, Tolerability, Efficacy and Pharmacokinetics of Copanlisib in Pediatric Patients

Bayer

Phase 1/2 Terminated
31 enrolled 17 charts
CNSLymphoidSarcoma

Lymphoma, Neuroblastoma, Recurrence, Rhabdomyosarcoma, Sarcoma, Ewing, Osteosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡